Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
In preclinical in vivo models of cancer, the induction of immunogenic cell death (ICD) sensitizes to subsequent immunotherapy. Several clinical trials now confirm that pretreatment with ICD-inducing anthracyclines sensitizes to immune checkpoint blockade targeting PD-1 and PD-L1 interaction. These f...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-10-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1637188 |